New therapeutic solutions for Behçet’s syndrome
| Autor: | Giuseppe Lopalco, Luca Cantarini, Giacomo Emmi, Mauro Galeazzi, Donato Rigante, Maria Teresa Bianco, Antonio Vitale, Florenzo Iannone |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Anti-Inflammatory Agents 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Tocilizumab Ustekinumab medicine Humans Immunologic Factors biologics Pharmacology (medical) 030203 arthritis & rheumatology Pharmacology therapy S syndrome Behçet's disease Tumor Necrosis Factor-alpha Behçet’s syndrome business.industry Behcet Syndrome Treatment options General Medicine autoinflammatory diseases medicine.disease Dermatology uveitis 030104 developmental biology Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA chemistry Drug Design Immunology Quality of Life Alemtuzumab Rituximab business Uveitis Interleukin-1 medicine.drug Inflammatory disorder |
| Zdroj: | Expert Opinion on Investigational Drugs. 25:827-840 |
| ISSN: | 1744-7658 1354-3784 |
| DOI: | 10.1080/13543784.2016.1181751 |
| Popis: | Behçet's syndrome (BS) is a systemic inflammatory disorder characterized by a wide range of potential clinical manifestations with no gold-standard therapy. However, the recent classification of BS at a crossroads between autoimmune and autoinflammatory syndromes has paved the way to new further therapeutic opportunities in addition to anti-tumor necrosis factor agents.This review provides a digest of all current experience and evidence about pharmacological agents recently described as having a role in the treatment of BS, including interleukin (IL)-1 inhibitors, tocilizumab, rituximab, alemtuzumab, ustekinumab, interferon-alpha-2a, and apremilast.IL-1 inhibitors currently represent the most studied agents among the latest treatment options for BS, proving to be effective, safe and with an acceptable retention on treatment. However, since BS is a peculiar disorder with clinical features responding to certain treatments that in turn can worsen other manifestations, identifying new treatment options for patients unresponsive to the current drug armamentarium is of great relevance. A number of agents have been studied in the last decade showing changing fortunes in some cases and promising results in others. The latter will potentially provide their contribution for better clinical management of BS, improving patients' quality of life and long-term outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|